A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis

The British Journal of Dermatology
Kim PappJ M Janes

Abstract

Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process. To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study. Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 weeks (Part A). Dose adjustment for 12 additional weeks was based on percentage improvement in the Psoriasis Area and Severity Index (PASI) score. The primary end point was Psoriasis Area and Severity Index (PASI) 75% (PASI-75) at 12 weeks for North American patients (n = 238); secondary end points were safety and efficacy measures in the entire population. At week 12, more North American patients in the 8-mg (43%) and 10-mg (54%) baricitinib groups than in placebo group (17%; P < 0·05) achieved PASI-75. All baricitinib-treated groups had greater mean changes from baseline in their PASI scores (P < 0·05) at 12 weeks and (except 2 mg) had higher rates of PASI-50 than the placebo group; statistically significant PASI-90 responses were achieved in the 8-m...Continue Reading

References

Oct 1, 1989·The British Journal of Dermatology·R CerioJ T Headington
Jan 1, 1983·Archives of Dermatological Research·J D BosR H Cormane
Oct 1, 1994·Clinical Pharmacology and Therapeutics·W J Jusko, H C Ko
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
Dec 12, 2003·Nature Reviews. Immunology·Ke Shuai, Bin Liu
Jun 14, 2005·The British Journal of Dermatology·K A PappUNKNOWN Etanercept Psoriasis Study Group
Dec 21, 2005·Archives of Dermatology·Joel M GelfandDavid J Margolis
Feb 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Peter J Murray
Oct 16, 2007·Journal of the American Academy of Dermatology·Alan MenterKim Papp
Jul 11, 2008·Immunological Reviews·Marko PesuJohn J O'Shea
Jul 31, 2009·The New England Journal of Medicine·Frank O NestleJonathan Barker
Sep 28, 2012·The Journal of Investigative Dermatology·Rosa ParisiUNKNOWN Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
Mar 25, 2014·Annual Review of Immunology·Michelle A LowesJames G Krueger

❮ Previous
Next ❯

Citations

Mar 5, 2016·Scandinavian Journal of Immunology·S Tavakolpour
May 11, 2016·Expert Opinion on Biological Therapy·Yael Renert-Yuval, Emma Guttman-Yassky
Jun 19, 2016·The British Journal of Dermatology·J Albrecht, S Gerdes
Jul 31, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
Nov 9, 2016·Current Opinion in Immunology·Kiyoshi HiraharaJohn J O'Shea
Jul 28, 2016·American Journal of Clinical Dermatology·Carolyn StullGil Yosipovitch
Feb 7, 2017·Expert Review of Clinical Immunology·Pablo OliveraLaurent Peyrin-Biroulet
Nov 9, 2016·Expert Review of Clinical Immunology·Ajesh B Maharaj, Vinod Chandran
Mar 8, 2017·Experimental Dermatology·Emma Guttman-YasskyMark G Lebwohl
Apr 11, 2017·Current Opinion in Rheumatology·Smriti K Raychaudhuri, Siba P Raychaudhuri
Dec 27, 2016·The Journal of Dermatological Treatment·Aniseh SamadiAlireza Firooz
May 31, 2017·European Journal of Immunology·Katharina WelschKamran Ghoreschi
Jun 25, 2017·Advances in Therapy·Yael Renert-Yuval, Emma Guttman-Yassky
Aug 2, 2017·Expert Opinion on Investigational Drugs·Adrien MirouseDavid Saadoun
Aug 26, 2016·American Journal of Physiology. Renal Physiology·Raimund PichlerKatherine R Tuttle
Nov 7, 2017·Nature Reviews. Drug Discovery·Daniella M SchwartzJohn J O'Shea
Nov 25, 2017·Expert Opinion on Pharmacotherapy·Abigail ClineSteven R Feldman
Dec 28, 2017·The Australasian Journal of Dermatology·Philippa DickisonSaxon D Smith
Jun 6, 2018·Current Opinion in Allergy and Clinical Immunology·Yael Renert-Yuval, Emma Guttman-Yassky
Jul 13, 2018·Journal of Leukocyte Biology·Massimo GadinaJohn J O'Shea
Aug 21, 2018·Expert Opinion on Drug Discovery·Dinesh AggarwalSonya Abraham
Nov 16, 2018·The Journal of Dermatological Treatment·Piotr CiechanowiczLidia Rudnicka
Feb 6, 2018·F1000Research·William VainchenkerStefan N Constantinescu
Jan 16, 2019·Expert Opinion on Investigational Drugs·Jorge Ocampo-GarzaAntonella Tosti
Apr 13, 2019·Immunological Reviews·Jillian M RichmondJohn E Harris
Jan 27, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·B ElewskiG Yosipovitch
Nov 16, 2019·The Journal of Experimental Medicine·Immo PrinzUlrich Mrowietz
Sep 27, 2019·Science Translational Medicine·Shuai ShaoJohann E Gudjonsson
Feb 15, 2020·Expert Opinion on Pharmacotherapy·Francesco CasoLuisa Costa
Mar 21, 2020·Expert Opinion on Emerging Drugs·Esther A BaloghSteven R Feldman
Mar 27, 2020·Chinese Medical Journal·Miao Chen, Sheng-Ming Dai
Jul 28, 2020·Expert Opinion on Emerging Drugs·Kayla FourzaliGil Yosipovitch
Sep 12, 2017·Expert Opinion on Pharmacotherapy·Luisa CostaFrancesco Caso
Sep 17, 2020·Expert Opinion on Biological Therapy·A Al-Janabi, R B Warren
Feb 1, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Anniina T VirtanenOlli Silvennoinen
Oct 28, 2019·Frontiers in Immunology·Michael D HowellPaul A Smith
Feb 20, 2020·Journal of Cellular Physiology·Arezoo HosseiniBehzad Baradaran
Apr 8, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Massimo GadinaJohn J O'Shea
Nov 12, 2017·Archives of Dermatological Research·Hanan Rabea NadaSally Mamdouh
Apr 5, 2018·Rheumatology·Douglas J VealeJean-Baptiste Telliez
May 28, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Thomas Litman
Jan 2, 2020·Dermatology and Therapy·Amanda Kvist-HansenLone Skov

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.